-

01:59:06 PM

DBVT Stock News

DBVT - DBV Technologies

09/21/22 5:45 PM

Nasdaq : DBVT

clinical trial

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and

RHEA-AI

neutral

09/07/22 4:30 PM

Nasdaq : DBVT

clinical trial

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the M odified Viaskin Peanut P atch in Peanut - Allergic Children Ages 4 to 7 Years DBV has finalized the VITESSE protocol after productive exchanges with the U.S. Food and Drug

RHEA-AI

neutral

09/02/22 4:30 PM

Nasdaq : DBVT

conferences

DBV Technologies to Present at Upcoming Investor Conferences

Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass?, Chief Executive Officer, DBV

RHEA-AI

neutral

08/01/22 4:30 PM

Nasdaq : DBVT

earnings

DBV Technologies Reports Second Quarter 2022 Financial Results

Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following recent ATM and PIPE offerings DBV continues to practice budget discipline measures; cash used in operating activities decreased more than 40% between

RHEA-AI

negative

07/27/22 4:30 PM

Nasdaq : DBVT

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATION Montrouge, France, July 27, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with O DDO BHF DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on

RHEA-AI

neutral

07/20/22 4:30 PM

Nasdaq : DBVT

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (Article 223-16 of the General Regulations of the Autorit? des March?s Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total

RHEA-AI

neutral

06/28/22 6:15 PM

Nasdaq : DBVT

conferences

DBV Technologies to Participate in Upcoming EAACI 2022 Congress

Montrouge, France, June 28, 2022 DBV Technologies to Participate in Upcoming EAACI 2022 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the hybrid in-person and virtual

RHEA-AI

neutral

06/16/22 1:30 AM

Nasdaq : DBVT

conferences

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass?, Chief Executive

RHEA-AI

neutral

06/09/22 2:55 AM

Nasdaq : DBVT

DBV Technologies Announces Private Placement Financing of $194 Million

Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 million private investment

RHEA-AI

neutral

06/07/22 4:30 PM

Nasdaq : DBVT

clinical trial

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

Montrouge, France, June 7, 2022 DBV Technologies Announce s Positive Topline Results from Phase 3 EPITOPE T rial of Viaskin Peanut in Peanut - Allerg ic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 ug met response criteria at 12 months, compared with 33.5% of subjects in the placebo

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next